Cytokeratin 14, Antibody

For Research Use Only. Not for use in diagnostic procedures.

IgG3

LL002

Mouse

Solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide.

Store at 2-8 degree C.

Small volumes of anti-KRT14 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Cytokeratin 14 (CK14) belongs to the acid subfamily of CKs (Type I) and is characteristic of stratifying epithelia (trachea, bronchi, cervix, epidermis, sweat glands). The antibody to CK14 is helpful to distinguish between stratifying epithelia and simple epithelia, which don't express this type of cytokeratins. Tumours of squamous cell origin will be stained with this antibody. Cytokeratins are a group of water-insoluble filamentous proteins. They are constituents of the cytoskeleton of epidermal cells and other epithelial cells. Up to now 20 different cytokeratins have been characterised by gel electrophoresis. They have been subdivided into a basic and an acid subfamily. Most frequently the nomenclature according to Moll et al. (1982) is used. Human cytokeratin 14.

Immunohistochemistry (IHC) Formalin/Paraffin

Working Concentration: (RTU) neat

51,561 Da[Similar Products]

Keratin, type I cytoskeletal 14

CK-14; K14  [Similar Products]

The nonhelical tail domain is involved in promoting KRT5-KRT14 filaments to self-organize into large bundles and enhances the mechanical properties involved in resilience of keratin intermediate filaments in vitro.

1. Moll R., Franke W.W., Schiller D.L., Geiger B., and Krepler R. (1982) The Catalog of Human Cytokeratins: Patterns of Expression in Normal Epithelia, Tumors and Cultured Cells. Cell 31; 11 ff. 2. Sun T.-T. Tseng S.C.G., Huang A.J.W., Cooper D., Lynch M.H., Weiss R., Eichner R., and Schermer (1985) Monoclonal antibody studies of keratin expression: A review. In: Intermediate Filaments, Wang E. et al. eds. N.Y. Acad. Sci. 455, pp 307 ff. 3. Harnden P. and Southgate J. (1997) Cytokeratin 14 as a marker of squamous differentiation in transitional cell carcinomas. J Clin Pathol. 50(12):1032-1033. 4. Sarbia M, Verreet P, Bittinger F, Dutkowski P, Heep H, Willers R, Gabbert HE. (1997) Basaloid squamous cell carcinoma of the esophagus: diagnosis and prognosis. Cancer 79(10):1871-1878. 5. Lakhani S.R., O'Hare M.J., Monaghan P., Winehouse J., Gazet J.C., Sloane J.P. (1995) Malignant myoepithelioma (myoepithelial carcinoma) of the breast: a detailed cytokeratin study. J. Clin. Pathol. 48(2):164-167.

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.